ArticleNeuropsychiatric disease and treatment2018
Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings.
Article in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review.Clinical pharmacology and therapeutics · 2022Pooled it
- Economic evaluation in psychiatric pharmacogenomics: a systematic review.The pharmacogenomics journal · 2021Pooled it
- Review and Consensus on Pharmacogenomic Testing in Psychiatry.Pharmacopsychiatry · 2021Pooled it
- Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.Ontario health technology assessment series · 2021Pooled it
- Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing.Frontiers in genetics · 2025Article
- Precision pharmacotherapy of atomoxetine in children with ADHD: how to ensure the right dose for the right person?Frontiers in pharmacology · 2024Review
- Implementing a Pharmacist-Led Primary Care Pharmacogenomics Medication Management Service.Innovations in pharmacy · 2024Article
- Article
- Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic.PCN reports : psychiatry and clinical neurosciences · 2022Review
- Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application.Molecular psychiatry · 2022Review
- Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals.Frontiers in pharmacology · 2022Article
- The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review.The pharmacogenomics journal · 2021Article
- Acceptability of Pharmacogenetic Testing among French Psychiatrists, a National Survey.Journal of personalized medicine · 2021Article
- Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS).Journal of translational medicine · 2021Article
- Literature Review Concerning the Challenges of Implementing Pharmacogenetics in Primary Care Practice.Cureus · 2020Review
- Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2020Article
- Pharmacogenetics in Psychiatry: An Update on Clinical Usability.Frontiers in pharmacology · 2020Review
- Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good.Human genomics · 2019Review
- Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Article
- Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of depression significantly impacts the patient, the health care system, and society, at large. Medication management guided by pharmacogenetics has been shown to increase therapeutic efficacy and improve symptoms in patients diagnosed with depression, but limited data are available on the cost savings of pharmacogenetic-guided interventions outside of psychiatric clinical specialties. Our study utilizes published health care costs and clinical patient outcome data to model the economic impact of pharmacogenetic-guided treatment for depression in a variety of clinical settings. Assuming a test cost of USD$2,000 for pharmacogenetic testing, the model predicts a savings of USD$3,962 annually per patient with pharmacogenetic-guided medication management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.